NO20050714L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20050714L
NO20050714L NO20050714A NO20050714A NO20050714L NO 20050714 L NO20050714 L NO 20050714L NO 20050714 A NO20050714 A NO 20050714A NO 20050714 A NO20050714 A NO 20050714A NO 20050714 L NO20050714 L NO 20050714L
Authority
NO
Norway
Prior art keywords
new connections
compounds
inhibiting
administered
expression
Prior art date
Application number
NO20050714A
Other languages
English (en)
Norwegian (no)
Inventor
Denis Evan Ryono
Neeraj Garg
Mahmoud Rahimi Gadim
Thomas Anders Wilson Ericsson
Lars Johan Malm
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab filed Critical Karobio Ab
Publication of NO20050714L publication Critical patent/NO20050714L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20050714A 2002-07-10 2005-02-10 Nye forbindelser NO20050714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0215978.8A GB0215978D0 (en) 2002-07-10 2002-07-10 Novel compounds
PCT/EP2003/007333 WO2004007430A2 (en) 2002-07-10 2003-07-08 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands

Publications (1)

Publication Number Publication Date
NO20050714L true NO20050714L (no) 2005-02-10

Family

ID=9940187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050714A NO20050714L (no) 2002-07-10 2005-02-10 Nye forbindelser

Country Status (20)

Country Link
US (1) US7153997B2 (de)
EP (2) EP1862450A2 (de)
JP (1) JP2005538076A (de)
KR (1) KR20050053590A (de)
CN (1) CN100347152C (de)
AT (1) ATE372980T1 (de)
AU (1) AU2003250908A1 (de)
BR (1) BR0312655A (de)
CA (1) CA2492046A1 (de)
DE (1) DE60316312T2 (de)
GB (1) GB0215978D0 (de)
HR (1) HRP20050015A2 (de)
IS (1) IS7649A (de)
MX (1) MXPA05000460A (de)
NO (1) NO20050714L (de)
PL (1) PL374733A1 (de)
RS (1) RS20050017A (de)
RU (1) RU2317287C2 (de)
WO (1) WO2004007430A2 (de)
ZA (1) ZA200500167B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
ITMI20110713A1 (it) * 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
EP1689383B1 (de) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Neue phosphor enthaltende thyromimetika
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
GB0406380D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
CN102203130B (zh) * 2010-08-06 2014-06-25 贝达药业股份有限公司 Glp-1衍生物及其应用
AU2011296737A1 (en) 2010-08-31 2013-04-11 Snu R&Db Foundation Use of the fetal reprogramming of a PPAR delta agonist
MX348467B (es) * 2011-04-08 2017-06-13 Bracco Imaging Spa Proceso para la preparación de un derivado sulfatado de 3,5-diiodo-o-[3-iodofenil]-l-tirosina.
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580550B1 (de) * 1992-07-21 1997-10-22 Novartis AG Oxamidsäure-Derivate als hypocholesterämische Mittel
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
JP4225791B2 (ja) * 2001-05-18 2009-02-18 キッセイ薬品工業株式会社 肝癌の予防または再発抑制剤

Also Published As

Publication number Publication date
IS7649A (is) 2005-01-14
EP1537073B1 (de) 2007-09-12
DE60316312T2 (de) 2008-06-05
CN1668579A (zh) 2005-09-14
KR20050053590A (ko) 2005-06-08
GB0215978D0 (en) 2002-08-21
ZA200500167B (en) 2006-07-26
CA2492046A1 (en) 2004-01-22
DE60316312D1 (de) 2007-10-25
MXPA05000460A (es) 2005-07-22
BR0312655A (pt) 2005-05-24
WO2004007430A3 (en) 2004-02-19
WO2004007430A2 (en) 2004-01-22
AU2003250908A1 (en) 2004-02-02
CN100347152C (zh) 2007-11-07
RU2317287C2 (ru) 2008-02-20
RU2005103406A (ru) 2005-06-27
US20060135614A1 (en) 2006-06-22
EP1862450A2 (de) 2007-12-05
US7153997B2 (en) 2006-12-26
PL374733A1 (en) 2005-10-31
RS20050017A (sr) 2007-08-03
JP2005538076A (ja) 2005-12-15
HRP20050015A2 (en) 2005-08-31
EP1537073A2 (de) 2005-06-08
ATE372980T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
BR0312655A (pt) Compostos
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
MXPA05006569A (es) Compuestos que inhiben la proteina cinasa-2 activada por la proteina cinasa activada por el mitogeno.
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
WO2003094845A3 (en) Pyridine-based thyroid receptor ligands
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
KR910014350A (ko) 3-아미노피페리딘 유도체 및 관련 질소 함유 헤테로사이클릭 화합물
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
WO2003027068A3 (en) Substituted amines for the treatment of neurological disorders
WO2003096983A3 (en) Method of treating dyslipidemic disorders
IS2593B (is) Heteróarýl-tetrahýdrópíoeridýl-sambönd gagnleg til meðferðar eða fyrirbyggingar á verkjum
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
TW200502221A (en) Novel lactams and uses thereof
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
WO2004066929A3 (en) Cycloalkyl containing anilide ligands for the thyroid receptor
WO2004067482A3 (en) Substituted anilide ligands for the thyroid receptor
DE60226906D1 (de) 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
NO993275D0 (no) FremgangsmÕte ved terapeutisk administrering av anti-CD40L-forbindelser
NO20072060L (no) 2-acylaminotiazolderivater
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
DE60330864D1 (de) Neue verbindungen, deren verwendung und herstellung
DK1641775T3 (da) 2-pyridinalkynderivater, der er anvendelige til behandling af smerter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application